INDEMNITY AGREEMENTIndemnity Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , is made by and between LUMENA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
LUMENA PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of March 7, 2014, by and among LUMENA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and the entities listed on EXHIBIT A hereto (each, an “Investor” and together the “Investors”).
LICENSE AGREEMENT BETWEEN LUMENA PHARMACEUTICALS, INC. AND SATIOGEN PHARMACEUTICALS, INC. EFFECTIVE AS OF FEBRUARY 8, 2011License Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of February 8, 2011 (the “Effective Date”), by and between Lumena Pharmaceuticals, Inc. (“Licensee”), a corporation organized and existing under the laws of the State of Delaware, and Satiogen Pharmaceuticals, Inc. (“Satiogen”), a corporation organized and existing under the laws of the State of Delaware. Licensee and Satiogen are sometimes referred to herein individually as a “Party” and collectively as “Parties.” The Parties agree as follows:
LICENSE AGREEMENT BETWEEN LUMENA PHARMACEUTICALS, INC. AND PFIZER INC. DATED June 1, 2012License Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of June 1, 2012 (the “Effective Date”), by and between Lumena Pharmaceuticals, Inc. (“Lumena”), a corporation organized and existing under the laws of the State of Delaware, and Pfizer Inc. (“Pfizer”), a corporation organized and existing under the laws of the State of Delaware. Lumena and Pfizer are sometimes referred to herein individually as a “Party” and collectively as “Parties.” The Parties agree as follows:
Research Triangle Park, NC 27709Lumena Pharmaceuticals, Inc. • April 2nd, 2014 • Pharmaceutical preparations
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCHResearch and Development Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • District of Columbia
This Agreement (“CRADA”) is based on the model Cooperative Research and Development Agreement (“Model CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
CONSULTING AGREEMENTConsulting Agreement • April 2nd, 2014 • Lumena Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of July 2, 2012 by and between LUMENA PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business located at 2520 Meridian Parkway, Suite 400, Durham, NC 27713 (“Company”), and ALANA MCNULTY (“Consultant”).
December 17, 2012 Michael GreyLumena Pharmaceuticals, Inc. • April 2nd, 2014 • Pharmaceutical preparations • California
December 20, 2012 Alejandro Dorenbaum, M.D.Lumena Pharmaceuticals, Inc. • April 2nd, 2014 • Pharmaceutical preparations • California
Lumena Pharmaceuticals, Inc. (the “Company”) is pleased to offer you the position of Chief Medical Officer on the terms set forth in this letter agreement (the “Agreement”). Your start date with the Company will be January 21, 2013, or such other date as we may mutually agree, subject to your signing and returning both this letter and the Company’s standard Employee Proprietary Information and Inventions Agreement.
February 4, 2014 Susan DubéLumena Pharmaceuticals, Inc. • April 2nd, 2014 • Pharmaceutical preparations
